Sciroppo di codeina

Descrizione Del Prodotto

1. Classification and Chemical Overview

Codeine Linctus is a licensed, single-constituent oral liquid pharmaceutical preparation formulated as an opioid antitussive (manufactured across the United Kingdom by licensed generic and proprietary suppliers such as Pinewood Laboratories, Thornton & Ross / Care, Bells Healthcare, and Galpharm). Chemically designated as $(5R,6S,9R,13S,14R)\text{-3-methoxy-17-methyl-4,5-epoxymorphin-6-ol phosphate hemihydrate}$, codeine phosphate is a naturally occurring or semi-synthetic phenanthrene alkaloid functioning primarily as an in vivo metabolic prodrug to morphine. Structurally, it consists of a pentacyclic morphinan skeleton featuring an ether (furan) bridge between carbon-4 and carbon-5, an aromatic A-ring with a methoxy moiety at carbon-3, a cyclohexenol C-ring with an allylic hydroxyl at carbon-6, and a tertiary $N$-methylated bridge at position 17. The carbon-3 methoxy group significantly diminishes its direct binding affinity for human opioid receptors relative to morphine. Its empirical molecular formula as the hemihydrate phosphate salt is $\text{C}_{18}\text{H}_{21}\text{NO}_3\cdot\text{H}_3\text{PO}_4\cdot\frac{1}{2}\text{H}_2\text{O}$, with an average molecular weight of $406.4\text{ g/mol}$ (unconjugated codeine base: $299.36\text{ g/mol}$).

Standard pharmaceutical presentations of Codeine Linctus in the UK consist of a clear, viscous, pale-straw or yellowish syrup delivering $15\text{ mg}$ of codeine phosphate per $5\text{ mL}$ of oral solution ($3\text{ mg/mL}$). Standard presentations are supplied in amber glass or polyethylene terephthalate (PET) dispensing bottles of $200\text{ mL}$ (delivering a cumulative dose of $600\text{ mg}$ of codeine phosphate) and $500\text{ mL}$ stock bottles (delivering $1,500\text{ mg}$). Standard non-active pharmaceutical excipients include a concentrated sucrose syrup vehicle (delivering a substantial glycemic load), liquid glucose, glycerol (E422), ethanol ($96\%$), sodium benzoate (E211), citric acid monohydrate (E330), and purified water (sugar-free variants substitute sucrose and liquid glucose with sorbitol and hydroxyethylcellulose).

Within the United Kingdom regulatory framework:

• Historic Pharmacy (P) Status and POM Reclassification: Historically, Codeine Linctus ($15\text{ mg}/5\text{ mL}$) was classified as a Pharmacy (P) medicine, legally available over the counter under the supervision of a registered community pharmacist. Following escalating evidence of organized pharmacy diversion, rapid physical dependence, and widespread recreational abuse:

  • The Medicines and Healthcare products Regulatory Agency (MHRA) executed a definitive regulatory intervention in February 2024, reclassifying all oral codeine linctus preparations as Prescription Only Medicines (POM).

  • Over-the-counter retail distribution is completely prohibited across the United Kingdom. Supply is legally restricted strictly to dispensing against a valid prescription issued by an authorized prescriber.

• Controlled Drug Scheduling: Under the Misuse of Drugs Act 1971, codeine is a Class B controlled substance. Under the Misuse of Drugs Regulations 2001, standard dilute compound codeine linctus formulations sit within Schedule 5 (CD Inv POM), which legally exempts them from statutory Safe Custody register-logging requirements, but leaves them subject to all baseline POM and Class B unlawful possession, supply, and importation penalties.

• NHS Formulary Positioning: Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff; however, routine prescription across NHS Integrated Care Boards (ICBs) is actively discouraged due to clinical consensus deeming opioid antitussives high-risk and largely obsolete.

In clinical toxicology and forensic drug monitoring, Codeine Linctus represents the primary domestic liquid vehicle diverted for the recreational preparation of “lean,” “purple drank,” or “dirty sprite.” Bottles diverted from legitimate supply chains command substantial illicit market premiums. This demand drives a parallel illicit market of counterfeit bottles filled with generic cough syrups adulterated with illicitly manufactured designer benzodiazepines (e.g., bromazolam) or high-potency synthetic nitazene opioids (e.g., protonitazene, metonitazene, isotonitazene), presenting extreme risks of unexpected, fatal central respiratory arrest.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of Codeine Linctus is defined by its role as an in vivo metabolic prodrug, producing central antitussive, sedative, analgesic, and respiratory-depressant effects through converted morphine:

• The Prodrug Paradigm and CYP2D6 Bioactivation:

  • Unaltered codeine ($3\text{-O-methylmorphine}$) displays exceptionally low intrinsic affinity for human $\mu$-opioid receptors (approximately $200\text{-fold}$ to $300\text{-fold}$ lower affinity than morphine), exhibiting negligible direct agonist efficacy at physiological concentrations.

  • Clinical pharmacological efficacy depends fundamentally on hepatic Phase I $O$-demethylation catalyzed by the polymorphic cytochrome P450 isoenzyme CYP2D6, which bioactivates approximately $5\text{ to }10\%$ of an ingested dose into free morphine. Converted morphine drives the vast majority of its central effects.

• Central Medullary Antitussive Suppression:

  • Codeine blunts the cough reflex through direct depressant action within the nucleus tractus solitarii (NTS) of the medulla oblongata:

  • Converted morphine binds to medullary $\mu$-opioid receptors, while parent codeine also interacts with central $\sigma_1$-receptors.

  • This raises the threshold of the sensory vagal cough center to afferent mechanical and chemical irritation, suppressing efferent motor signaling directed to the diaphragm, pharynx, and intercostal musculature.

• Postsynaptic $\mu$-Opioid (MOP) Receptor Signal Transduction:

  • Converted morphine acts as a full agonist at human $\mu$-opioid receptors located across the brainstem, periaqueductal gray (PAG), thalamus, and dorsal horn of the spinal cord:

  • Receptor binding activates coupled heterotrimeric inhibitory $G_{\alpha i/o}$ proteins.

  • The dissociated $G_{\alpha}$ subunit inhibits adenylyl cyclase, lowering intracellular cyclic adenosine monophosphate (cAMP).

  • Concurrently, the $G_{\beta\gamma}$ dimer inhibits presynaptic voltage-gated N-type calcium ($Ca^{2+}$) channels, arresting the vesicular exocytosis of primary excitatory neurotransmitters (substance P, calcitonin gene-related peptide [CGRP], and L-glutamate).

  • Simultaneously, it activates postsynaptic G-protein-coupled inwardly rectifying potassium (GIRK) channels, driving cellular potassium ion efflux. The resulting membrane hyperpolarization stabilizes resting membrane potentials below firing thresholds, dampening ascending sensory transmission.

• Respiratory and Enteric Depression:

  • Activation of $\mu$-opioid receptors within the pontomedullary respiratory pacemakers (pre-Bötzinger complex) blunts the sensitivity of central chemoreceptors to arterial carbon dioxide tension ($\text{PaCO}_2$) and hypoxia, resulting in dose-dependent central respiratory depression.

  • In the gastrointestinal tract, stimulation of myenteric $\mu$-receptors inhibits propulsive peristalsis and secretomotor fluid transport while increasing sphincter tone, driving profound constipation.

3. Approved UK Clinical Indications and Therapeutic Scope

Where formally authorized in the United Kingdom, Codeine Linctus possesses an exceptionally narrow, specialized licensed therapeutic scope:

• Symptomatic Relief of Dry, Non-Productive Cough (Adults $\ge 18$ Years):

  • Indicated for the short-term symptomatic relief of distressing, non-productive dry cough in adults aged 18 years and older when non-opioid alternatives have failed.

  • Standard Adult Dosing: $5\text{ to }10\text{ mL}$ ($15\text{ to }30\text{ mg}$ codeine phosphate) taken orally three to four times daily as clinically indicated.

  • Ceiling Dosing: A maximum single dose of $10\text{ mL}$ ($30\text{ mg}$) and a maximum cumulative daily ceiling of $40\text{ mL}$ ($120\text{ mg}$ codeine phosphate) in any 24-hour period.

  • Duration Limit: Prescriptions must not exceed 3 to 5 days. If cough paroxysms persist, thorough clinical re-evaluation is required to exclude underlying malignant, infectious, or asthmatic pulmonary disease.

• Strict Contraindication in Paediatrics (<18 Years):

  • In compliance with MHRA directives and European Medicines Agency (EMA) safety referrals, all codeine-containing cough and cold medications are strictly contraindicated in children and adolescents under 18 years of age. This restriction was mandated following fatal cases of respiratory arrest in pediatric patients who were post-mortem identified as CYP2D6 ultra-rapid metabolizers.

Clinical Positioning and NICE Guidance

National Institute for Health and Care Excellence (NICE) guidelines and Clinical Knowledge Summaries (CKS: Cough) explicitly advise against the routine prescription of codeine-containing cough suppressants for acute cough. Systematic reviews confirm that evidence of superior clinical efficacy over non-opioid demulcents is negligible, whereas the risks of rapid physical tolerance, dependence, fatal accidental overdose, and respiratory compromise are substantial. First-line clinical interventions prioritize non-pharmacological demulcents (e.g., honey and lemon mixtures or glycerol-based non-medicated linctuses).

In non-medical, recreational drug subcultures:

• “Lean” / “Purple Drank” Misuse: Recreational users mix substantial volumes of Codeine Linctus ($50\text{ to }200\text{ mL}$, delivering $150\text{ to }600\text{ mg}$ of codeine phosphate) into sweetened carbonated beverages, co-ingesting it with first-generation sedating antihistamines (principally promethazine). Promethazine prevents codeine-induced nausea, blocks peripheral histamine-induced itching, and amplifies central sedative-dissociative euphoria.

• Opioid Self-Medication: Misused by individuals with underlying opioid use disorders (OUD) to suppress the distressing autonomic storms and myalgias of acute opioid withdrawal.

4. Pharmacokinetic Profile and Metabolic Fate

The pharmacokinetic behavior of Codeine Linctus is characterized by rapid liquid gastrointestinal absorption, extensive first-pass hepatic biotransformation, parallel metabolic pathways, and critical CYP2D6 pharmacogenetic polymorphism:

Hepatic Metabolic Pathways

1. Glucuronidation (Major Route, $\sim 70\text{ to }80\%$): Direct Phase II conjugation catalyzed by UDP-glucuronosyltransferase UGT2B7 converts codeine to codeine-6-glucuronide (C6G). C6G possesses modest intrinsic $\mu$-opioid receptor affinity and contributes partially to systemic analgesia and sedation.

2. $O$-Demethylation via CYP2D6 (Bioactivation Route, $\sim 5\text{ to }10\%$): Cytochrome P450 2D6 cleaves the 3-methoxy ether group to generate active free morfina. Converted morphine is subsequently conjugated by UGT2B7 into active morphine-6-glucuronide (M6G) and neurotoxic morphine-3-glucuronide (M3G).

3. $N$-Demethylation via CYP3A4 ($\sim 10\%$): CYP3A4 mediates $N$-demethylation to yield norcodeine, an inactive metabolite that undergoes subsequent glucuronidation.

The CYP2D6 Pharmacogenetic Dynamic

• Poor Metabolisers (PMs; $7\text{ to }10\%$ of Caucasian cohorts): Individuals possessing two non-functional CYP2D6 alleles (e.g., *3, *4, *5, *6). PMs lack the enzymatic capacity to bioactivate codeine into morphine; they experience negligible antitussive or euphoric effects, yet remain fully susceptible to codeine-induced constipation, nausea, and histamine release.

• Extensive (Normal) Metabolisers (EMs): Display standard therapeutic conversion of codeine to morphine.

• Ultra-Rapid Metabolisers (UMs; up to $10\%$ of Caucasians, up to $29\%$ of specific North African, Middle Eastern, and Mediterranean populations): Individuals harboring gene duplications or amplifications of functional CYP2D6 alleles (e.g., *1xN, *2xN). UMs clear codeine rapidly into massive concentrations of circulating free morphine. In UMs, standard therapeutic doses ($15\text{ to }30\text{ mg}$) can precipitate catastrophic, unexpected central respiratory depression, profound comatose stupor, and fatal apnea.

5. Physiological Effects and Adverse Event Spectrum

Therapeutic administration of Codeine Linctus suppresses cough paroxysms and induces mild sedation. In supratherapeutic, recreational, or chronic exposure, multi-system toxicities emerge:

• Histaminergic Reactions (Very Common, $\ge 1/10$):

  • Codeine acts as a direct, non-immunological secretagogue triggering cutaneous and systemic mast cell degranulation. Ingestion of therapeutic or recreational doses drives acute systemic histamine release, presenting as intense generalized pruritus (itching), cutaneous facial flushing, urticaria, conjunctival injection, and bronchospasm (hazardous in asthmatics).

• Gastrointestinal and Autonomic Disruptions (Very Common to Common, $\ge 1/100$ to $\ge 1/10$):

  • Profound Constipation: Enteric $\mu$-opioid receptor activation inhibits propulsive peristalsis, increases internal anal sphincter tone, and blunts secretomotor fluid transport, risking severe fecal impaction or stercoral ulceration in chronic users.

  • Nausea and vomiting: Direct chemical stimulation of dopamine $D_2$ e $\mu$-opioid receptors in the chemoreceptor trigger zone (CTZ) of the area postrema.

  • Xerostomia (dry mouth) and epigastric discomfort.

  • Sphincter of Oddi Spasm: Marked constriction of biliary and pancreatic sphincters elevates intrabiliary pressure, precipitating acute biliary colic or exacerbating pancreatitis.

• Central Nervous System and Neuropsychiatric Toxicity (Common):

  • Drowsiness, daytime somnolence, lightheadedness, dizziness, and cognitive clouding.

  • Euphoria (reinforcing psychological dependence) or paradoxical dysphoria, restlessness, and anxiety.

  • Confusion and visual hallucinations (disproportionately observed in elderly patients).

• Severe, Emergent and Life-Threatening Hazards:

  • Fatal Central Respiratory Depression: The primary cause of death in codeine poisoning. Blunting of the brainstem pre-Bötzinger complex results in severe bradypnea ($<8\text{ breaths/min}$), progressive cyanosis, stupor advancing to deep unarousable coma, hypercapnic acidosis, and fatal hypoxic cardiac arrest.

  • Synergistic Depressant Collapse (“Lean” Toxicity): Co-ingestion of Codeine Linctus alongside alcohol, benzodiazepines, or sedating antihistamines (e.g., promethazine) synergistically suppresses pontine and medullary respiratory drive, exponentially increasing fatal poisoning rates.

  • Physical Dependence and Acute Opioid Withdrawal Syndrome: Continuous daily exposure exceeding 1 to 2 weeks drives neuroadaptation. Abrupt discontinuation precipitates a severe withdrawal syndrome: autonomic hyperactivity (sinus tachycardia, hypertension, profuse diaphoresis), gastrointestinal cramping, diarrhea, piloerection (“cold turkey”), pupillary dilation (mydriasis), severe myalgias, and unremitting insomnia.

  • The Counterfeit Nitazene Hazard: Bottles sold illicitly under counterfeit Codeine Linctus labels frequently contain synthetic nitazene opioids (such as metonitazene or protonitazene). Nitazenes exhibit potencies tens to hundreds of times higher than morphine, precipitating sudden, refractory respiratory collapse that fails to respond to conventional single doses of naloxone.

6. Contraindications, Drug Interactions, and Clinical Precautions

Safe clinical evaluation, prescribing, and emergency management of individuals exposed to Codeine Linctus require adherence to opioid safety guidelines, pharmacogenetic screening, and respiratory risk stratification:

• Contraindications:

  • Known CYP2D6 Ultra-Rapid Metabolisers: Absolute contraindication due to the certainty of life-threatening morphine toxicity at standard doses.

  • Paediatric Age Under 18 Years: Absolute contraindication in all children and adolescents under 18 years of age.

  • Acute Respiratory Compromise: Absolute contraindication in acute respiratory depression, severe chronic obstructive pulmonary disease (COPD), respiratory failure, or acute severe asthma.

  • Paralytic Ileus or Obstructive Bowel Disease: Absolute contraindication due to the risk of precipitating toxic megacolon or bowel perforation.

  • Head Injury and Raised Intracranial Pressure (ICP): Opioid-induced hypoventilation causes $\text{CO}_2$ retention, driving cerebral vasodilation that dangerously spikes intracranial pressure.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication during or within 14 days of MAOI therapy (risks hyperpyrexic crises and central collapse).

  • Pregnancy and Breastfeeding: Absolute contraindication during breastfeeding (morphine distributes into maternal milk, presenting severe risks of fatal neonatal apnea); chronic use during pregnancy precipitates neonatal opioid withdrawal syndrome (NOWS).

• Drug Interactions:

  • Central Nervous System Depressants (e.g., Alcohol, Benzodiazepines, Antipsychotics, Sedating Antihistamines): Synergistic, catastrophic depression of medullary ventilatory drive; co-ingestion is the primary driver of fatal recreational syrup overdoses.

  • CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine, Bupropion, Quinidine): Blocks the metabolic conversion of codeine to active morphine, completely abolishing antitussive and analgesic efficacy while leaving adverse histaminergic and gastrointestinal side effects unopposed.

  • CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St John’s Wort): Accelerates clearance to inactive norcodeine, significantly reducing clinical efficacy.

  • Anticholinergic Agents (e.g., TCAs, Antihistamines, Antimuscarinics): Compounded paralytic burden on the gastrointestinal tract and bladder, substantially increasing the risk of paralytic ileus and acute urinary retention.

• Clinical Precautions and Emergency Overdose Management (“Red Flags”):

  • Acute Overdose Resuscitation Protocol: Patients presenting to emergency departments (999/A&E) with the classic opioid toxidrome (bradypnea $<8\text{ breaths/min}$, pinpoint pupils [miosis], and coma/unresponsiveness) require immediate emergency stabilization:

    • Airway and Oxygenation: Prioritize airway patency, position in the recovery position, deliver high-flow oxygen, and support ventilation with bag-valve-mask or endotracheal intubation.

    • Targeted Naloxone Administration: Administer the opioid antagonist naloxone ($400\text{ mcg}$ IV initially, repeating or escalating to $800\text{ mcg}$ to $2\text{ mg}$ every 2 to 3 minutes up to $10\text{ mg}$ as clinically indicated to restore adequate spontaneous respiration).

    • Prolonged Observation Window: Because converted morphine and active glucuronides have elimination half-lives ($2\text{ to }3.5\text{ hours}$) that outlast intravenous naloxone ($30\text{ to }60\text{ minutes}$ duration of action), patients must be observed under continuous pulse oximetry and clinical monitoring for a minimum of 4 to 6 hours to detect and manage re-narcotization.

    • Nitazene Suspicion: In patients who ingested counterfeit bottles containing synthetic nitazene opioids, massive cumulative doses of naloxone ($>4\text{ to }10\text{ mg}$ IV or continuous IV infusion) may be required to maintain ventilation.

  • Sugar Content in Diabetic Patients: Standard Codeine Linctus contains high concentrations of sucrose and liquid glucose; ingestion of recreational volumes introduces a substantial carbohydrate load that can trigger acute glycemic instability in patients with diabetes mellitus.

  • Detoxification Protocols: Dependent individuals attempting to discontinue codeine linctus must not be stopped abruptly without clinical support. Management involves structured stabilization and gradual dose reduction using licensed oral opioid substitution therapy (e.g., buprenorphine or methadone) under NHS community addiction recovery services.

  • Driving Safety Warning: Codeine impairs cognitive processing and reaction times. Under Section 5A of the Road Traffic Act 1988, driving with specified controlled drugs in the blood above statutory limits is an offence; while a statutory medical defense applies when the medicine is taken strictly in accordance with prescription instructions, patients must be warned that driving while impaired remains an offence under Section 4 of the Act.

Ulteriori Informazioni